Filing Details
- Accession Number:
- 0000950170-24-038630
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-03-29 16:05:11
- Reporting Period:
- 2024-03-27
- Accepted Time:
- 2024-03-29 16:05:11
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1426800 | Assembly Biosciences Inc. | ASMB | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1807214 | A Jason Okazaki | C/O Assembly Biosciences, Inc. Two Tower Place, 7Th Floor South San Francisco CA 94080 | Ceo And President | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2024-03-27 | 392 | $12.87 | 14,180 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person.
- Reflects equitable adjustment of the number of shares of common stock beneficially owned by the reporting person as a result of a 1-for-12 reverse stock split of the Issuer's common stock effected February 9, 2024, which is exempt from reporting pursuant to Rule 16a-9.
Billionaire Hedge Funds
